JPWO2022081711A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022081711A5 JPWO2022081711A5 JP2023523609A JP2023523609A JPWO2022081711A5 JP WO2022081711 A5 JPWO2022081711 A5 JP WO2022081711A5 JP 2023523609 A JP2023523609 A JP 2023523609A JP 2023523609 A JP2023523609 A JP 2023523609A JP WO2022081711 A5 JPWO2022081711 A5 JP WO2022081711A5
- Authority
- JP
- Japan
- Prior art keywords
- covid
- cov
- sars
- antiviral composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000025721 COVID-19 Diseases 0.000 claims 32
- 241001678559 COVID-19 virus Species 0.000 claims 27
- 230000000840 anti-viral effect Effects 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229940125777 fusion inhibitor Drugs 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940052404 nasal powder Drugs 0.000 claims 1
- 229940100656 nasal solution Drugs 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091915P | 2020-10-14 | 2020-10-14 | |
| US63/091,915 | 2020-10-14 | ||
| US202063107429P | 2020-10-29 | 2020-10-29 | |
| US63/107,429 | 2020-10-29 | ||
| US202163139302P | 2021-01-19 | 2021-01-19 | |
| US202163139306P | 2021-01-19 | 2021-01-19 | |
| US63/139,302 | 2021-01-19 | ||
| US63/139,306 | 2021-01-19 | ||
| US202163144606P | 2021-02-02 | 2021-02-02 | |
| US63/144,606 | 2021-02-02 | ||
| US202163145453P | 2021-02-03 | 2021-02-03 | |
| US63/145,453 | 2021-02-03 | ||
| PCT/US2021/054789 WO2022081711A1 (en) | 2020-10-14 | 2021-10-13 | Lipopeptide fusion inhibitors as sars-cov-2 antivirals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504225A JP2024504225A (ja) | 2024-01-31 |
| JPWO2022081711A5 true JPWO2022081711A5 (https=) | 2024-10-18 |
| JP2024504225A5 JP2024504225A5 (https=) | 2024-10-18 |
Family
ID=81208578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523609A Pending JP2024504225A (ja) | 2020-10-14 | 2021-10-13 | Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としてのリポペプチド融合阻害物質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240226304A1 (https=) |
| EP (1) | EP4228673A4 (https=) |
| JP (1) | JP2024504225A (https=) |
| KR (1) | KR20240038643A (https=) |
| CA (1) | CA3195563A1 (https=) |
| IL (1) | IL302066A (https=) |
| TW (1) | TW202229316A (https=) |
| WO (1) | WO2022081711A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022159372A1 (en) * | 2021-01-22 | 2022-07-28 | Decoy Therapeutics, Inc. | Methods and compositions for treating infections |
| CA3235784A1 (en) * | 2021-10-22 | 2023-04-27 | Wisconsin Alumni Research Foundation | Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease |
| WO2024016011A2 (en) * | 2022-07-15 | 2024-01-18 | The Trustees Of Columbia University In The City Of New York | Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses |
| CN115746148B (zh) * | 2022-10-14 | 2023-09-12 | 中国医学科学院病原生物学研究所 | 具有冠状病毒rbd和膜融合抑制多肽的蛋白质及其作为冠状病毒抑制剂的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5788178B2 (ja) * | 2008-01-23 | 2015-09-30 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | ウィルス感染症の治療のための組成物及び方法 |
| US10172961B2 (en) * | 2014-05-07 | 2019-01-08 | Cornell University | Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them |
| CA3094136A1 (en) * | 2018-01-31 | 2019-08-08 | Verra Therapeutics LLC | Methods and compositions for inhibiting adam9 biological activities |
| CN111732637B (zh) * | 2020-05-25 | 2022-03-01 | 上海交通大学 | 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用 |
| CN111560054A (zh) * | 2020-06-16 | 2020-08-21 | 哈尔滨吉象隆生物技术有限公司 | 抑制新型冠状病毒感染的多肽及其筛选方法 |
-
2021
- 2021-10-13 US US18/249,058 patent/US20240226304A1/en active Pending
- 2021-10-13 JP JP2023523609A patent/JP2024504225A/ja active Pending
- 2021-10-13 EP EP21880997.8A patent/EP4228673A4/en active Pending
- 2021-10-13 KR KR1020237016292A patent/KR20240038643A/ko active Pending
- 2021-10-13 CA CA3195563A patent/CA3195563A1/en active Pending
- 2021-10-13 WO PCT/US2021/054789 patent/WO2022081711A1/en not_active Ceased
- 2021-10-13 IL IL302066A patent/IL302066A/en unknown
- 2021-10-14 TW TW110138190A patent/TW202229316A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024170583A5 (https=) | ||
| Goyal et al. | Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review | |
| KR20140069091A (ko) | 기침 및 기침으로 인한 발작 치료 | |
| US11007187B1 (en) | Medicine for Covid-19 and treatment | |
| JP2026000993A (ja) | 新ペプチド | |
| WO2023169557A1 (zh) | 一种次黄碱衍化合物在制备治疗肺纤维化药物中的应用 | |
| JPWO2022081711A5 (https=) | ||
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| JPWO2022096708A5 (https=) | ||
| JPWO2021191592A5 (https=) | ||
| CN111320662B (zh) | 一类n-苄基取代的二脒那秦衍生物及其药物用途 | |
| JP2010189301A (ja) | 新型インフルエンザ感染症に対する医薬組成物およびその利用 | |
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| JPWO2021216891A5 (https=) | ||
| CN105769842A (zh) | 大黄二蒽酮的用途及抗病毒药物 | |
| Maharajan et al. | Pharmaceutical, biological agents, and vaccines under clinical trials for COVID-19 and roles of pharmacists to combat COVID-19, an update | |
| WO2021049980A1 (ru) | Новые составы для лечения и профилактики вирусных заболеваний | |
| CN111568900A (zh) | 吲哚美辛在抗冠状病毒感染中的应用 | |
| EP3906934B1 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| WO2002005802A1 (en) | Method of fundamentally treating common cold | |
| WO2024096742A1 (en) | SARS-CoV-2 BINDING POLYPEPTIDE | |
| JP2007291072A (ja) | 医薬組成物 | |
| CN117562913A (zh) | 连翘活性成分组合在制备拮抗SARS-CoV-2突变毒株的药物中的应用 | |
| EP4612174A1 (en) | Sars-cov-2 binding antibody |